Natasha A. Mesinkovska, MD, PhD, who spoke on the live satellite symposium "Gamechangers in Alopecia Areata" at the SBS 2023 meeting, speaks out about comorbid conditions often seen in alopecia areata patients, as well as her personal approach to treatment.

Questions:

1. We’ve heard a lot about comorbid conditions often seen in patients with alopecia areata. Do you have any pearls you’d like to share regarding screening or multidisciplinary care for patients with comorbidities?

2. What is your personal approach to developing a treatment plan for your patients with alopecia areata? 

3. Thank you for your time today, Dr Mesinkovska. This was very informative. Is there anything else you’d like to add?

Date: February 10, 2023

Brett King, MD, PhD, who spoke on the live satellite symposium "Gamechangers in Alopecia Areata" at the SBS 2023 meeting, speaks out about the rising use of JAK inhibitors to treat patients with alopecia areata.

Questions:

1. JAK inhibitors are taking the dermatology field by storm, with several approvals for multiple dermatologic conditions over the past couple of years. What is it that makes JAK inhibitors a gamechanger for treatment of alopecia areata?

2. In 2022, the first ever targeted treatment for alopecia areata, baricitinib, was approved by the FDA for adult patients. What additional treatments or FDA approvals can we expect to see in 2023?

3. Thank you for your time today, Dr King. This was fantastic. Is there anything else you’d like to add?

Date: February 10, 2023

Brittany Craiglow, MD, who spoke on the live satellite symposium "Gamechangers in Alopecia Areata" at the SBS 2023 meeting, shares her personal approach to treating pediatric patients with alopecia areata.

Questions:

1. What is your personal approach to developing a treatment plan with your patients and/or their caregivers? Do find yourself utilizing shared decision-making or other nuances to communicating with patients and caregivers?

2. You mainly treat pediatric and adolescent patients for hair loss in your clinical practice. Are there any specific nuances you’d like to share in regard to treating pediatric versus adult patients suffering from hair loss?

3. Thank you for your time today, Dr Craiglow. This was wonderful. Is there anything else you’d like to add?

Recorded Date: February 10, 2023

Elaine Siegfried, MD, who spoke on the live satellite symposium "Infants and Atopic Dermatitis" at the MOPD 2023 meeting, shares her expert advice for formulating a treatment plan and incorporating newer treatment options when managing pediatric patients with atopic dermatitis.

Questions:

• With recently expanded age indications for therapeutic agents to treat pediatric AD, what steps should clinicians consider when formulating a treatment plan for their younger patients?
• The treatment landscape for atopic dermatitis in pediatric patients has shown much growth over the past couple of years. How do you foresee the treatment landscape continuing to change in 2023?
• This was excellent, Dr Siegfried, thank you for your time. Is there anything else you’d like to add?

Date: February 10, 2023

Lawrence Schachner, MD, chair of the MOPD meeting and expert faculty who spoke on the live satellite symposium "Infants and Atopic Dermatitis", shares clinical pearls for early and accurate diagnosis of atopic dermatitis in younger pediatric patients, as well as challenges often faced when assessing pediatric patients with skin of color.

Questions:

• Can you share your top pearls for early and accurate recognition of atopic dermatitis in infants?
• What gaps do you feel persist in the diagnosis and assessment of atopic dermatitis in infants, particularly those with skin of color?
• Thank you for your time today, Dr Schachner. This was fantastic. Is there anything else you’d like to add?

Date: February 10, 2023

Mercedes Gonzalez, MD, who spoke on the live satellite symposium "Infants and Atopic Dermatitis" at the MOPD 2023 meeting, shares clinical pearls for improving communication with patients and caregivers of patients with atopic dermatitis.

Questions:

• Caregivers often voice concerns regarding safety and side effects of newer systemic treatments for atopic dermatitis. What can clinicians do to better educate and reassure their patients and caregivers? How does shared decision-making factor into this?
• What gaps do you feel persist regarding the communication between clinicians and their patients/caregivers? What can clinicians do to address these gaps?
• Thank you for your time today, Dr Gonzalez. This was very informative. Is there anything else you’d like to add?

February 10, 2023

LiVDerm is very excited to announce our two Co-Chairs for the 21st Annual South Beach Symposium (SBS) meeting, taking place in 2023, Dr. Michael Gold, MD and Dr. David Goldberg, MD, JD.

Our theme, Deeper Than the Surface, was born based on what sets SBS apart from any of the other hundreds of dermatology meetings out there and that's how SBS truly delivers equal parts Clinical and Aesthetic Dermatology Education.

Both Dr. Gold and Dr. Goldberg have been a part of SBS since its inception 21 years ago, and they have evolved with the meeting. Although many in the industry would associate them as aesthetic KOL's and thought leaders, there is much more to them than their 'surface' suggests; they both spend a great deal of time in their practice treating patients medical dermatology conditions. Featuring Dr. Goldberg, a MOHS surgeon listed in headlines for new acne therapies and the longtime Chair of our Cutaneous Oncology Track at SBS, along with Dr. Gold and his extensive clinical trial experience, which he heads in his Nashville practice, this podcast shares an in-depth discussion of how much of their actual clinic time is spent on medical dermatology and their involvement in breaking clinical trials for medical dermatology therapies. Listen in now to hear a truly insightful review of SBS as an educational meeting and how it has changed with leaders like Drs. Gold and Goldberg at the helm.

Peter Lio, MD, LiVDerm faculty and atopic dermatitis expert, shares pearls from his session at the SBS 2022 event regarding the efficacy and safety of IL-13 inhibitors for treatment of AD.

• What factors should clinicians consider when selecting a biologic or systemic therapy to manage atopic dermatitis?
• Effectively and promptly diagnosing atopic dermatitis can be a bit tricky at times. What is your personal approach for effective diagnosis?
• Which patients would benefit most from an integrative approach to managing atopic dermatitis?
• How can clinicians execute effective shared decision-making strategies in the management of chronic skin conditions?

Christopher Bunick, MD, PhD, LiVDerm faculty and member of the SBS Planning Committee, shares key takeaways from his session at the SBS 2022 event regarding IL-13 inhibitors for treatment of AD and the underlying disease pathogenesis.

• With the several ongoing advances in the availability of more treatment options for managing atopic dermatitis, how can the practicing clinician best select the most appropriate treatment option that will address the underlying causes of disease progression?
• As with most treatment options for chronic conditions, side effects often occur. What considerations should clinicians remember when discussing treatment-related adverse events with their patients?
• Atopic dermatitis is stated to impact several areas of a patient’s life, including the quality. How can clinicians best address this issue from a patient-centered perspective?
• What key takeaways should clinicians consider when constructing a management plan for chronic illnesses such as moderate to severe atopic dermatitis?

We are honored to speak to Klint Peebles, MD, the chair of LiVDerm's Sexual and Gender Diverse Dermatology Summit: Fundamentals and Practical Pearls and past chair of the American Academy of Dermatology’s Expert Resource Group on Sexual and Gender Diverse Health. Dr. Peebles, a board-certified dermatologist with Kaiser Permanente, Mid-Atlantic Permanente Medical Group, has extensive clinical, leadership, and research expertise in sexual and gender diverse health and gender-affirming dermatology. Dr. Peebles currently serves on the LGBTQ Health Specialty Section Council of the American Medical Association. Dr. Peebles mentions some of the key reasons why you don't want to miss the Sexual and Gender Diverse Dermatology Summit: Fundamentals and Practical Pearls in California October 15-16, 2022! - Register here: www.livderm.org/live-events/sexual-and-gender-minority/

Topics Dr. Peebles covers include:

• We are so excited to welcome you as the conference chair of our upcoming Sexual and Gender Diverse Dermatology Summit in Southern California this October 15-16. What unique experiences do you bring to this conference and why is this patient population so important in the dermatologic field?
• Although there are certain aspects of aesthetic medicine in caring for sexual and gender diverse patients, would you consider this area of the discipline falling under the category of medical dermatology, or is it not necessary to differentiate? Do you expect practitioners of both cosmetic and general dermatology to benefit from the Summit?
• Your wealth of experience, leadership, and advocacy in the field of better medical care for the sexual and gender diverse patient population has no doubt improved outcomes and quality of life. Can you tell us about some of your career highlights and moments when you could see actionable change as a result of your efforts?
• The Sexual and Gender Diverse Summit, taking place within SBS: West Coast Derm this October 2022 at the Terranea Resort is a milestone event for LiVDerm. Do you think the location of the event just outside of Los Angeles, California, is indicative of the sexual and gender diverse population and the providers who see them? Do you see events like this someday soon being held in smaller, more rural regions of the U.S. where fewer resources or social determinants may mean that sexual and gender diverse patients face even larger roadblocks to care?
• Is the field of dermatology seeing improvements in nondiscrimination, acceptance, welcoming environments, affirming language, and dedicated initiatives to improve safety, and can you explain some of those efforts within the context of guidelines or policy?

www.livderm.org